What is the recommended dose of cefepime (Intramuscular injection cefepime) for the pediatric population?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefepime Dosing for Pediatric Patients

For pediatric patients ≥2 months of age with normal renal function, administer cefepime 50 mg/kg intravenously or intramuscularly every 8-12 hours (maximum 2 g per dose), with every 8-hour dosing reserved for febrile neutropenia or severe infections. 1

Standard Dosing by Age and Indication

Infants and Children (2 months to 16 years)

  • Standard dose: 50 mg/kg per dose every 12 hours for most infections 1, 2
  • Febrile neutropenia: 50 mg/kg per dose every 8 hours (maximum 2 g per dose) 1
  • Maximum single dose: Do not exceed 2 g per dose regardless of weight 1

Route of Administration

  • Intravenous: Administer over approximately 30 minutes 1
  • Intramuscular: Acceptable alternative with 82% bioavailability (range 61-124%), though absorption results in slightly prolonged half-life (1.9 vs 1.8 hours) 2

Pharmacokinetic Rationale

The every 12-hour dosing interval is supported by robust pharmacokinetic data:

  • Elimination half-life: Averages 1.7 hours in pediatric patients ≥2 months 2
  • Renal clearance: 1.9 mL/min/kg with 57-89% recovered unchanged in urine 2
  • Volume of distribution: 0.35 L/kg at steady state 2
  • Pharmacokinetic modeling demonstrates that 50 mg/kg every 12 hours achieves adequate time above MIC (100% fT>MIC) for pathogens with MIC ≤8 mg/L 2

Special Considerations

Renal Impairment

Dose adjustment is mandatory for patients with creatinine clearance ≤60 mL/min to prevent neurotoxicity 1. Recent evidence suggests:

  • Normal/augmented renal clearance: Consider continuous infusion (100 mg/kg/day) for critically ill children to optimize PK/PD targets 3
  • Renal failure: 100 mg/kg/day divided every 12 hours over 30 minutes is adequate 3

Age-Specific Nuances

  • Infants <6 months: May have slightly prolonged half-life and mean residence time, but no dose adjustment is required for those ≥2 months 2
  • Neonates <2 months: Cefepime is not the preferred agent; guidelines recommend ceftazidime (150 mg/kg/day divided every 8 hours) or cefotaxime instead 4

Clinical Context from Guidelines

While the FDA label provides cefepime dosing, pediatric infectious disease guidelines preferentially recommend ceftriaxone or ceftazidime for most serious infections in young infants:

  • For febrile infants 8-60 days: Ceftriaxone 50-100 mg/kg/day is preferred over cefepime 4
  • For community-acquired pneumonia: Ceftriaxone or cefotaxime are first-line; cefepime is not specifically mentioned 4

Important Caveats

  • Neurotoxicity risk: Particularly in patients with renal impairment receiving unadjusted doses; discontinue if neurotoxicity occurs 1
  • Therapeutic drug monitoring: Mandatory in critically ill children given cefepime's narrow therapeutic window 3
  • Galaxy Container limitation: Should only be used in pediatric patients requiring the entire 1 or 2 gram dose, not fractions thereof 1
  • Cross-hypersensitivity: May occur in up to 10% of patients with penicillin allergy 1

References

Research

Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.